Clover Health Publishes Q2 2026 Shareholder Q&A After Earnings

What Happened Clover Health Investments, Corp. announced on August 20, 2026 that it published a list of responses to frequently asked supplemental questions submitted in connection with the company’s second quarter 2026 earnings announcement. The supplemental Q&A is furnished as Exhibit 99.1 to the Form 8-K and is also posted on Clover Health’s investor relations website. The filing was signed by Clay Thornton, Interim Chief Financial Officer (Principal Financial Officer).

Key Details

• Filing date: August 20, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Exhibit: 99.1 — Supplemental Shareholder Q&A dated August 20, 2026; also made available on the company’s investor relations page.
• No new financial statements, earnings metrics, or restatements were included in the filing; the submission is supplemental commentary following the Q2 2026 earnings release.
• Report signed by Clay Thornton, Interim CFO (Item 9.01 lists the exhibit and cover page interactive data).

Why It Matters This disclosure provides additional context and management responses to shareholder questions following Clover Health’s Q2 2026 earnings, improving transparency and investor engagement. Because the filing contains supplemental Q&A rather than new financial results, it does not change previously reported quarterly earnings figures but may clarify management’s outlook, decisions, or operational details discussed in the earnings release.